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Thomas Klopstock1*† and Klaus A Kuhn2†Abstract
We report the development of an international registry for Neurodegeneration with Brain Iron Accumulation (NBIA),
in the context of TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration), an EU-FP7 – funded project.
This registry aims to combine scattered resources, integrate clinical and scientific knowledge, and generate a rich
source for future research studies. This paper describes the content, architecture and future utility of the registry
with the intent to capture as many NBIA patients as possible and to offer comprehensive information to the
international scientific community.
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increasing success owing to the rapid development of
tools for defining phenotypic and genetic determinants.
The elucidation of disease pathogenesis may simultan-
eously trigger the identification of pathway-specific
treatment targets, but the development of disease-
modifying medications is often hampered by the frag-
mentation of efforts and the low number of available
patients. The integration of scattered resources is, there-
fore, crucial for the success of future scientific accom-
plishments. Here we report the inception of a central
data repository for a group of rare disorders collectively
called Neurodegeneration with Brain Iron Accumulation
(NBIA).
NBIA has an estimated prevalence of 1–3 / 106 and
consists of several genetically-defined entities that clinic-
ally often overlap but also have unique features (Table 1).
The neuropathological hallmarks include iron accumula-
tion associated with neuronal loss and gliosis, which ap-
pear as hypointense lesions (iron) with or without
hyperintense patches (gliosis) on T2-weighted MRI in
most NBIA forms. The “eye of the tiger” sign (a hypoin-
tense area with a hyperintense center) in the globus* Correspondence: thomas.klopstock@med.uni-muenchen.de
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reproduction in any medium, provided the orpallidus is seen in Pantothenate Kinase-Associated Neu-
rodegeneration (PKAN) (1). Iron in the brain can be
assessed by using dual spin-echo and multiple gradient-
echo MRI sequences, which allow monitoring an endo-
phenotype of the disease. Biological heterogeneity of
NBIA is reflected by the differential appearance of vari-
ous neuronal inclusions in the genetically defined sub-
entities. However, shared functions of the affected genes
are also recognized in the maintenance of membrane
phospholipids and the regulation of mitochondrial en-
ergy metabolism, explaining the degenerative features of
neuropathology (2). Even though the excess of iron
appears pathogenic, molecular causes and consequences
of its accumulation remain unknown. An iron-chelating
agent, deferiprone, approved for systemic iron-overload
disorders, is currently being tested in the largest sub-
group of NBIA, PKAN (Table 1). This deferiprone trial
with the associated biobank and patient registry repre-
sent core work packages in TIRCON (Treat Iron-
Related Childhood-Onset Neurodegeneration), an inter-
national consortium supported by the European Com-
mission´s Seventh Framework Programme.
As a central data repository of TIRCON, the NBIA
registry (www.tirconregistry.org) manages links to the
deferiprone trial database, the NBIA image archive and
biobank. The collected information includes demograph-
ics, family and patient history, clinical signs, neurological
exam, laboratory results, brain iron assessment andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 NBIA disorders
Disease Gene Inheritance Clinical presentation MRI
Classic form: Early onset – rapid progression
Pantothenate kinase-associated
neurodegeneration (PKAN)
PANK2 autosomal recessive Gait abnormality, dystonia, dysarthria, corticospinal
involvement, pigmentary retinopathy
“Eye-of-the-tiger” sign in the GP
Mitochondrial membrane protein-associated
neurodegeneration (MPAN)
C19orf12 autosomal recessive Speech and gait difficulties, progressive
spastic paraparesis, dystonia, optic atrophy,
axonal motor neuropathy, cognitive decline
Increased iron in GP and SN; “Eye of the
tiger” sign very rare
Fatty-acid hydroxylase-associated
neurodegeneration (FAHN)
FA2H autosomal recessive Onset with focal dystonia and gait
impairment, ataxia, dysarthria, spastic
quadriparesis, nystagmus, visual loss,
no or mild cognitive impairment and
seizures in late stages; overlaps with
some HSP syndromes and phenotypes
of leukodystrophies
Abnormal iron in GP and SN, optic,
cerebellar and brainstem atrophy,
confluent subcortical and periventricular
hyperintensity, thinning of the CC
PLA2G6-associated neurodegeneration
(PLAN) –Infantile neuroaxonal dystrophy (INAD)
PLA2G autosomal recessive Severe psychomotor regression, hypotonia,
peripheral motor neuropathy, hyperreflexia,
tetraparesis, ataxia, gait abnormalities
Cerebellar atrophy, abnormal iron in GP
and other nuclei
Atypical form: Later onset – slower progression
Atypical pantothenate kinase-associated
neurodegeneration (PKAN)
PANK2 autosomal recessive Speech abnormalities, depression, impulsivity,
aggression, emotional instability
Eye-of-the-tiger sign or variants of it in
the GP or other signs of increased iron
and gliosis in the GP
Atypical mitochondrial membrane
protein-associated neurodegeneration (MPAN)
C19orf12 autosomal recessive Psychiatric features, parkinsonism,
dystonia-parkinsonism, motor axonal
neuropathy, mild gait difficulty, optic
atrophy, cognitive decline
Increased iron in GP and SN
Neuroferritinopathy FTL autosomal dominant Huntington´s disease-like presentation:
adult-onset chorea or dystonia,
orofacial action dystonia, cognitive decline
Abnormal iron and later cystic changes
in the basal ganglia
Aceruloplasminemia CP autosomal recessive Diabetes mellitus, retinal degeneration,
blepharospasm, facial and neck dystonia,
chorea, tremor, dysarthria,
ataxia – typically adult onset
Pathological iron in both the brain and
viscera; in the brain: GP, striatum,
thalami, dentate nuclei
In the viscera: liver
PLA2G6-associated neurodegeneration
(PLAN) –neuroaxonal dystrophy (NAD)
PLA2G6 autosomal recessive Progressive dystonia, dysarthria, language
delay, corticospinal signs, psychiatric
features and social difficulties or similar to
but later onset version of INAD
Cerebellar and optic nerve atrophy
Iron may or may not be increased
PLA2G6-associated neurodegeneration
(PLAN) – dystonia-parkinsonism
PLA2G6 autosomal recessive Parkinsonism, dystonia-parkinsonism Iron may be increased in SN an striatum
Other NBIA form
Kufor-Rakeb syndrome ATP13A2 autosomal recessive Juvenile onset parkinsonism, corticospinal




Generalized brain atrophy, increased
iron in the caudate and lenticular





















Table 1 NBIA disorders (Continued)
Woodhouse-Sakati Syndrome C2orf37 autosomal recessive Hypogonadism, diabetes, alopecia, hearing
loss, mental retardation, progressive
generalized and focal dystonia, dysarthria,
cognitive decline
Increased iron in GP, SN and other
nuclei; white matter abnormalities
Static Encephalopathy with
Neurodegeneration in Adulthood (SENDA)
In progress autosomal recessive Childhood onset cognitive impairment
without progression; in adult age sudden
onset progressive dystonia-parkinsonism
and corticospinal signs.
Increased iron in the GP and SN; on
T1W MRI, hyperintensity with central
band of hypointensity in the SN;
cerebral and cerebellar atrophy
Legend to Table.
The table summarizes the currently known entities collected under the umbrella of NBIA. Transitional phenotypes are increasingly observed within the spectrum etween the extremes of the early and late onset forms
due to the routine use of molecular genetics in clinical practice.
Increased iron in the brain is reflected by hypointensity on T2-weighted MRI scans, and is typically detected in nuclei where some iron is normally present: GP, S putamen, caudate, dentate nuclei and red nuclei. The
“eye of the tiger” sign refers to an ovoid area of hypointensity with a hyperintense center corresponding to increased iron and gliosis, respectively, within the GP The histological substrates of iron accumulation
include the astrocytes, microglia / macrophages, neurons, neuropil and the perivascular space. In the same regions, axonal spheroids, neuronal loss, gliosis and d yelination may also be present. Ceroid lipofuscin





T1W MRI: T1-weighted magnetic resonance imaging.
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course is captured by standardized scales measuring dys-
tonia severity, quality of life and sleep, functional inde-
pendence, cognition, motor functioning and activity of
daily living. The annually entered information enables a
longitudinal reconstruction of the disease course, while
genomic, transcriptomic, proteomic and metabolomic
data from research on the biobank specimens contribute
additional dimensions to the registry.
The technical development of the registry involved sig-
nificant preparatory works. During an initial phase of six
months, existing local databases and their datasets were
analysed in order to specify data elements which are har-
monized and most useful for the international NBIA
registry. For quick and easy data entry by participating
clinicians, web-based forms have been created. Manage-
ment of directly identifying data are restricted to the re-
spective sites, and only patient codes (pseudonyms) will
be entered into the registry database. Together with
these patient pseudonyms, codes identifying biospeci-
mens, images, and data in the deferiprone trial database
are kept in the registry and safeguarded by a sophisti-
cated security and privacy architecture.
The registry’s security and privacy concept builds upon
the security architecture of the German mitoNET re-
pository (3), which has been successfully running for
more than three years. Access rights are strictly role-
based, and pseudonyms are kept spatially and
organizationally separate from the registry database stor-
ing medical/research data. Double coding is used for all
pseudonyms, which are additionally secured by encryp-
tion. In terms of the US Health Insurance Portability
and Accountability Act, protected health information
compliant with the “limited data set” definition is stored.
For the use of data and biosamples, agreements have
been specified and approved by local ethics committees
and data protection authorities. Future research propo-
sals will be reviewed by the TIRCON’s Scientific Steering
Committee (SSC). If the proposal is approved, pseud-
onymous or anonymous data will be released to the fu-
ture investigator, depending on the proposal and the
vote of the SSC. As an additional safeguard, re-
identification attempts are prohibited by the data use
agreements.
In summary, this registry longitudinally collects multi-
dimensional information on NBIA disorders to provide a
rich resource for future natural history studies, evalua-
tions of clinical and paraclinical surrogates or potential
predictors of the disease, and correlation analyses of
clinical subentities with pathogenic mutations, alleles of
disease modifying genes, results of “-omics” and environ-
mental factors. It will support the design of placebo-con-
trolled, randomized, double-blind clinical trials, and
allow probing which clinical, imaging or laboratoryfeatures of the disease may be modified by a treatment
modality. The NBIA registry represents a paradigm fos-
tering integration of international resources for the en-
hancement of scientific synergism and future research
activities in a group of rare diseases.
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